Overview

Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

Fludarabine may be of benefit to prevent rejection of grafted solid organs in children during chemo-immunotherapy treatment for post transplant lymphoproliferative diseases (PTLDs).

Phase:

Phase 4

Details

Lead Sponsor:

A.O. Ospedale Papa Giovanni XXIII

Treatments:

Cyclophosphamide
Doxorubicin
Fludarabine
Fludarabine phosphate
Liposomal doxorubicin
Rituximab
Vidarabine